Navigation Links
Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
Date:11/2/2009

first and only FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. BYETTA is not insulin and should not be taken instead of insulin. BYETTA is not recommended to be taken with insulin. BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis.

BYETTA provides sustained A1C control and low incidence of hypoglycemia when used alone or in combination with metformin or a thiazolidinedione, with potential weight loss. BYETTA is not a weight loss product. BYETTA was approved in April 2005 and has been used by more than one million patients since its introduction. For full prescribing information, visit www.BYETTA.com.

Important Safety Information for BYETTA® (exenatide) injection

Based on post-marketing data, BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. The risk for getting low blood sugar is higher if BYETTA is taken with another medicine that can cause low blood sugar, such as a sulfonylurea. BYETTA should not be used in people who have severe kidney problems, and should be used with caution in people who have had a kidney transplant. Patients should talk with their healthcare provider if they have severe problems with their stomach, such as delayed emptying of the stomach (gastroparesis) or problems with digesting food. Severe allergic reactions can happen with BYETTA.

The most common side effects with BYETTA include nausea,
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amylin Pharmaceuticals Reports Third Quarter Financial Results
2. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
5. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
6. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
7. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
8. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
9. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
10. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
11. Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Conn. , May 17, 2013 /PRNewswire-iReach/ -- ... and recombinant proteins, is placing renewed emphasis on ... the rise as a number of factors are ... for pharmaceutical makers and their delivery device partners ... previously refractory conditions, the growing trend toward self-administration ...
(Date:5/17/2013)... 17, 2013  Boehringer Ingelheim will contribute to ... the American Thoracic Society International Conference (ATS 2013) ... 17 – 22. Data will highlight ... treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® ... investigational compounds for asthma, idiopathic pulmonary fibrosis (IPF) ...
(Date:5/17/2013)... (EURONEXT: SAN and NYSE: SNY ) announced today ... examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), ... primary endpoint assessed the proportion of patients achieving >/=35% ... previous trials, the most common adverse events were anemia, ... at an upcoming medical congress. MF ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
(Date:5/19/2013)... 19, 2013 The legal team at ... in a concerted effort to connect women and families ... control drugs Yaz, Yasmin & Ocella with the legal ... information on the notorious birth control drugs as well ... , Yaz, Yasmin & Ocella were very popular ...
(Date:5/18/2013)... 18, 2013 Daily Gossip issued a press ... review on their page. John Colston, Daily Gossip’s spokesperson, told ... Hadsall’s revolutionizing 14-Day Rapid Fat Loss Plan . ... carbs are healthy at a time when nutritionists and fat ... caloric products. , The diet is based on the ...
(Date:5/18/2013)... Also known as bariatric surgery , ... surgery that guarantees patients long-term weight loss. Dr. Naim ... give readers a brief tutorial on this revolutionary weight ... New York City’s Mount Sinai School of Medicine. After ... fellowship in Minimally Invasive Bariatric Surgery. He has also ...
(Date:5/18/2013)... Children who swallow high-powered magnets often need surgery and ... a new study. The researchers, from the Louisiana ... more than 79 percent of children who swallowed very ... procedure, in which a tube containing a camera is ... these cases can be treated through observation or by ...
(Date:5/18/2013)... FL (May 18, 2013) There are significant ... commonly used to diagnose or treat gastrointestinal problems, ... (DDW). , A study by New York ... more objective testing may substantially reduce the cost ... Although GERD is believed to affect nearly 25 ...
Breaking Medicine News(10 mins):Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Everything You Need to Know About Lap Band Surgery 2Health News:Everything You Need to Know About Lap Band Surgery 3Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2
... to keep smoking, experts say , TUESDAY, June 15 (HealthDay News) ... a B vitamin are half as likely as others to develop ... doesn,t mean that smokers should hit the vitamin aisle instead of ... as one amino acid, to fewer cases of lung cancer, it ...
... a unanimous decision, the Florida Advisory Council on Radiation ... Radiation Oncology,s (ASTRO) patient protection plan. , ASTRO,s Board ... of the Society,s patient safety and quality assurance projects, ... January 28-31, 2010. The goal of the plan is ...
... The Sixth Book in ... the 21st Century and Presents the Essence and Secrets of Ancient Teachings of Tao Along ... , ... the newly released sixth book of his best-selling Soul Power Series, Tao I: The Way of ...
... book by researchers at Oregon State University uses the snapshot-in-time ... types of animal and plant fossils not just what ... behaved, especially at the moment of death. All kinds ... mating and reproductive instincts, to the behavior of pathogenic microbes ...
... ... calves by kayak and and view them just a few meters from ... is a national park, UNESCO World Heritage Site, and the only calving ... camping, whale watch cruise and van tour of the peninsula,s unique wildlife, ...
... found cases missed by routine screening, researchers say , TUESDAY, ... the methods for early detection of HIV, researchers sought to ... increase the number of cases that could be detected early, ... Nucleic acid tests look for traces of genetic material from ...
Cached Medicine News:Health News:Vitamin B6 Tied to Lowered Lung Cancer Risk 2Health News:Vitamin B6 Tied to Lowered Lung Cancer Risk 3Health News:Florida radiation council endorses ASTRO patient protection plan 2Health News:TAO l: The Way of All Life, by Zhi Gang Sha Reaches #6 on New York Times Bestseller List 2Health News:TAO l: The Way of All Life, by Zhi Gang Sha Reaches #6 on New York Times Bestseller List 3Health News:A new view of fossils: The behavior of ancient life forms 2Health News:Kayak With Whales Argentina Patagonia - From Our Exclusive Beach Camp 2Health News:Gene-Based Detection Method Might Spot HIV Earlier 2
Straight shafts with two point fixation. Tips separated by 3 mm, each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with dull finish....
Curved shafts with 0.5 mm, 1 x 2 teeth. Serrated handle with thumb catch lock and polished finish....
5 mm jaws with teeth provide secure fixation of occular structures....
Straight shafts with fine Pierse type tips. Flat smooth handle with dull finish....
Medicine Products: